240 related articles for article (PubMed ID: 32587297)
21. Decitabine enhances targeting of AML cells by CD34
Cany J; Roeven MWH; Hoogstad-van Evert JS; Hobo W; Maas F; Franco Fernandez R; Blijlevens NMA; van der Velden WJ; Huls G; Jansen JH; Schaap NPM; Dolstra H
Blood; 2018 Jan; 131(2):202-214. PubMed ID: 29138222
[TBL] [Abstract][Full Text] [Related]
22. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia?
Ferrara F
Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815
[TBL] [Abstract][Full Text] [Related]
23. Decitabine and all-trans retinoic acid synergistically exhibit cytotoxicity against elderly AML patients via miR-34a/MYCN axis.
Cao Y; Liu Y; Shang L; Wei W; Shen Y; Gu Q; Xie X; Dong W; Lin Y; Yue Y; Wang F; Gu W
Biomed Pharmacother; 2020 May; 125():109878. PubMed ID: 32006898
[TBL] [Abstract][Full Text] [Related]
24. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
[TBL] [Abstract][Full Text] [Related]
25. Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition.
Zhang P; Brinton LT; Williams K; Sher S; Orwick S; Tzung-Huei L; Mims AS; Coss CC; Kulp SK; Youssef Y; Chan WK; Mitchell S; Mustonen A; Cannon M; Phillips H; Lehman AM; Kauffman T; Beaver L; Canfield D; Grieselhuber NR; Alinari L; Sampath D; Yan P; Byrd JC; Blachly JS; Lapalombella R
Clin Cancer Res; 2021 Apr; 27(8):2352-2366. PubMed ID: 33542077
[TBL] [Abstract][Full Text] [Related]
26. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
27. Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.
Cagnetta A; Soncini D; Orecchioni S; Talarico G; Minetto P; Guolo F; Retali V; Colombo N; Carminati E; Clavio M; Miglino M; Bergamaschi M; Nahimana A; Duchosal M; Todoerti K; Neri A; Passalacqua M; Bruzzone S; Nencioni A; Bertolini F; Gobbi M; Lemoli RM; Cea M
Haematologica; 2018 Jan; 103(1):80-90. PubMed ID: 29025907
[TBL] [Abstract][Full Text] [Related]
28. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
29. 5-azacytidine enhances efficacy of multiple chemotherapy drugs in AML and lung cancer with modulation of CpG methylation.
Füller M; Klein M; Schmidt E; Rohde C; Göllner S; Schulze I; Qianli J; Berdel WE; Edemir B; Müller-Tidow C; Tschanter P
Int J Oncol; 2015 Mar; 46(3):1192-204. PubMed ID: 25501798
[TBL] [Abstract][Full Text] [Related]
30. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF
Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219
[TBL] [Abstract][Full Text] [Related]
31. Use of decitabine for patients with refractory or relapsed acute myeloid leukemia: a systematic review and meta-analysis.
Ma YY; Zhao M; Liu Y; Zhao DF; Wang LX; Chen XP; Li L
Hematology; 2019 Dec; 24(1):507-515. PubMed ID: 31242832
[No Abstract] [Full Text] [Related]
32. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Shaker S; Bernstein M; Momparler LF; Momparler RL
Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
[TBL] [Abstract][Full Text] [Related]
33. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.
Scott SA; Lakshimikuttysamma A; Sheridan DP; Sanche SE; Geyer CR; DeCoteau JF
Exp Hematol; 2007 Feb; 35(2):263-73. PubMed ID: 17258075
[TBL] [Abstract][Full Text] [Related]
34. Genomic impact of transient low-dose decitabine treatment on primary AML cells.
Klco JM; Spencer DH; Lamprecht TL; Sarkaria SM; Wylie T; Magrini V; Hundal J; Walker J; Varghese N; Erdmann-Gilmore P; Lichti CF; Meyer MR; Townsend RR; Wilson RK; Mardis ER; Ley TJ
Blood; 2013 Feb; 121(9):1633-43. PubMed ID: 23297133
[TBL] [Abstract][Full Text] [Related]
35. Low-dose cytarabine and hypomethylating agents for Down syndrome with acute myeloid leukemia.
Ramakrishnan R; Munir F; Quesada AE; Hitzler J; Cuglievan B
Pediatr Blood Cancer; 2024 Jun; 71(6):e30974. PubMed ID: 38523255
[No Abstract] [Full Text] [Related]
36. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
38. Hypomethylating Agents as a Therapy for AML.
Gardin C; Dombret H
Curr Hematol Malig Rep; 2017 Feb; 12(1):1-10. PubMed ID: 28286907
[TBL] [Abstract][Full Text] [Related]
39. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine.
Chuang JC; Yoo CB; Kwan JM; Li TW; Liang G; Yang AS; Jones PA
Mol Cancer Ther; 2005 Oct; 4(10):1515-20. PubMed ID: 16227400
[TBL] [Abstract][Full Text] [Related]
40. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition.
Raneros AB; Minguela A; Rodriguez RM; Colado E; Bernal T; Anguita E; Mogorron AV; Gil AC; Vidal-Castiñeira JR; Márquez-Kisinousky L; Bulnes PD; Marin AM; Garay MCG; Suarez-Alvarez B; Lopez-Larrea C
Oncotarget; 2017 May; 8(19):31959-31976. PubMed ID: 28404876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
